Patents by Inventor Ala Fishman

Ala Fishman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7704506
    Abstract: The present invention generally relates to a new approach for the therapy of allergic responses, based on targeted elimination of cells expressing the Fc?RI receptor by a chimeric cytotoxin FC2?-3-PE40. A sequence encoding amino acids 301-437 of the Fc region of the mouse IgE molecule was genetically fused to PE40—a truncated form of PE lacking the cell binding domain. The chimeric protein, produced in E. coli, specifically and efficiently kills mouse mast cell lines expressing the Fc?RI receptor, as well as primary mast cells derived from bone marrow. The present invention provides a chimeric protein for targeted elimination of Fc?RI expressing cells especially useful for the therapy of allergic responses. The said chimeric protein is comprised of a cell targeting moiety for Fc?RI expressing cells and a cell killing moiety. The preferred killing moiety is the bacterial toxin Pseudomonas exotoxin (PE). This Pseudomonas exotoxin is a product of Pseudomonas aeruginosa.
    Type: Grant
    Filed: July 31, 2007
    Date of Patent: April 27, 2010
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Ala Fishman, Shai Yarkoni, Haya Lorberboum-Galski
  • Publication number: 20090082549
    Abstract: The present invention generally relates to a new approach for the therapy of allergic responses, based on targeted elimination of cells expressing the Fc?RI receptor by a chimeric cytotoxin FC2?-3-PE40. A sequence encoding amino acids 301-437 of the Fc region of the mouse IgE molecule was genetically fused to PE40—a truncated form of PE lacking the cell binding domain. The chimeric protein, produced in E. coli, specifically and efficiently kills mouse mast cell lines expressing the Fc?RI receptor, as well as primary mast cells derived from bone marrow. The present invention provides a chimeric protein for targeted elimination of Fc?RI expressing cells especially useful for the therapy of allergic responses. The said chimeric protein is comprised of a cell targeting moiety for Fc?RI expressing cells and a cell killing moiety. The preferred killing moiety is the bacterial toxin Pseudomonas exotoxin (PE). This Pseudomonas exotoxin is a product of Pseudomonas aeruginosa.
    Type: Application
    Filed: July 31, 2007
    Publication date: March 26, 2009
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Ala Fishman, Shai Yarkoni, Haya Lorberboum-Galski
  • Patent number: 6919079
    Abstract: The present invention generally relates to a new approach for the therapy of allergic responses, based on targeted elimination of cells expressing the Fc?RI receptor by a chimeric cytotoxin Fc2?-3-PE40. A sequence encoding amino acids 301-437 of the Fc region of the mouse IgE molecule was genetically fused to PE40—a truncated form of PE lacking the cell binding domain. The chimeric protein, produced in E. coli, specifically and efficiently kills mouse mast cell lines expressing the Fc?RI receptor, as well as primary mast cells derived from bone marrow. The present invention provides a chimeric protein for targeted elimination of Fc?RI expressing cells especially useful for the therapy of allergic responses. The said chimeric protein is comprised of a cell targeting moiety for Fc?RI expressing cells and a cell killing moiety. The preferred killing moiety is the bacterial toxin Pseudomonas exotoxin (PE). This Pseudomonas exotoxin is a product of Pseudomonas aeruginosa.
    Type: Grant
    Filed: December 18, 1996
    Date of Patent: July 19, 2005
    Assignee: Yissum Research Company of the Hebrew University of Jerusalem
    Inventors: Ala Fishman, Shai Yarkoni, Haya Lorberboumgalski
  • Publication number: 20030158390
    Abstract: The present invention generally relates to a new approach for thetherapy of allergic responses, based on targeted elimination of cells expressing the Fc&egr;RI receptor by a chimeric cytotoxin FC2′-3-PE40. A sequence encoding amino acids 301-437 of the Fc region of the mouse IgE molecule was genetically fused to PE40′—a truncated form of PE lacking the cell binding domain. The chimeric protein, produced in E. coli, specifically and efficiently kills mouse mast cell lines expressing the Fc&egr;RI receptor, as well as primary mast cells derived from bone marrow. The present invention provides a chimeric protein for targeted elimination of Fc&egr;RI expressing cells especially useful for the therapy of allergic responses. The said chimeric protein is comprised of a cell targeting moiety for Fc&egr;RI expressing cells and a cell killing moiety. The preferred killing moiety is the bacterial toxin Pseudomonas exotoxin (PE). This Pseudomonas exotoxin is a product of Pseudomonas aeruginosa.
    Type: Application
    Filed: March 14, 2002
    Publication date: August 21, 2003
    Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM
    Inventors: Ala Fishman, Shai Yarkoni, Haya Lorberboumgalski